MBI 594AN: Phase II

MGIXF said preliminary results showed that MBI 594AN gave a 32% reduction in

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE